SG3 Management’s RAPT Therapeutics RAPT Stock Holding History

SG3 Management’s Portfolio RAPT Stock Details RAPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-1,375	Closed	-$350K	–	1205
2021 Q2	$350K	Buy	+1,375	New	+$257K	0.01%	716

Other funds holding RAPT

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Ponoi Management San Francisco, California $73.2M AUM 23.44% 1-Year Est. Return

Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

KXA

KPCB XV Associates Menlo Park, California $35.8M AUM 57.59% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

SG3 Management's RAPT Position: Q3 2021 in Review

SG3 Management sold out of RAPT Therapeutics (RAPT) in Q3 2021, closing a stake of 2,500 shares — an estimated $661K sold.

SG3 Management first reported a position in RAPT in Q1 2021 and held it in 2 quarters. The position peaked at $636K in Q2 2021. 106 funds tracked by Wall St. Rank hold RAPT as of Q3 2021.

SG3 Management reported no remaining RAPT Therapeutics position as of Q3 2021 after selling out during the quarter.
SG3 Management sold 2,500 RAPT Therapeutics shares in Q3 2021, an estimated $661K.
SG3 Management first reported a position in RAPT Therapeutics in Q1 2021 and held it in 2 quarters.
SG3 Management's RAPT Therapeutics position peaked at $636K in Q2 2021.
106 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q3 2021.

Based on SG3 Management's 13F filing for Q3 2021, filed 15 Nov 2021.